BRUSSELS, Belgium - Boehringer Ingelheim and Ablynx have come together on a $265 million deal to explore the use of Ablynx' novel class of therapeutic proteins - nanobodies - in treatments for Alzheimer's disease. Andreas Barner, Boehringer Ingelheim's vice chairman and head of pharma research, described it as a "powerful and unique technology." (BioWorld International) Read More
